Confined or spread disease-Spread into the peritoneum - Page 2 of 4 Posts on Medivizor
Navigation Menu

Confined or spread disease-Spread into the peritoneum Posts on Medivizor

HIPEC combined with surgery is effective in colorectal cancer with peritoneal metastasis

HIPEC combined with surgery is effective in colorectal cancer with peritoneal metastasis

Posted by on Nov 7, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients with early stage peritoneal metastasis (PM; when the cancer spreads to the abdominal lining). Researchers suggested that HIPEC may benefit these patients. Some background The peritoneal region is the second...

Read More

Malnutrition caused by pre-surgery chemotherapy is associated with rectal cancer treatment outcomes

Posted by on Jun 3, 2016 in Colorectal cancer | 0 comments

In a nutshell This study investigated the association between malnutrition caused by pre-surgery chemotherapy and radiation (CRT) and rectal cancer treatment tolerance and anastomotic leakage (AL; leakage of intestinal fluids). Researchers reported that malnutrition related to CRT is associated with treatment tolerance and AL. Some background CRT...

Read More

Stricter adherence to chemotherapy drug dosage recommendations improve survival outcomes in stage 3 colon cancer patients

Stricter adherence to chemotherapy drug dosage recommendations improve survival outcomes in stage 3 colon cancer patients

Posted by on Nov 6, 2015 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effect of chemotherapy drug dose on the survival outcomes of stage 3 colon cancer patients.  Some background Relative dose intensity (RDI) refers to the proportion of the standard drug dose received during chemotherapy. Previous studies have shown that an RDI greater than 70% is associated with better...

Read More

Can removal of the primary tumor improve survival outcomes in stage IV colorectal cancer?

Can removal of the primary tumor improve survival outcomes in stage IV colorectal cancer?

Posted by on Jun 9, 2014 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to evaluate the impact of primary tumor removal and lymph node dissection on disease outcome in metastatic colorectal cancer.  Some background Approximately 15-20% of patients with colorectal cancer are diagnosed with distant metastasis (spread of the cancer) despite widespread screening. While in some...

Read More

New predictors of prognosis in colon cancer?

New predictors of prognosis in colon cancer?

Posted by on Feb 18, 2014 in Colorectal cancer | 0 comments

In a nutshell The current study examined whether the proteins versican and lumican were predictive of prognosis among colon cancer patients. Some background Colon cancer treatments vary depending on the type and stage of the disease. Patients with advanced cancer, which has invaded the surrounding lymph nodes, usually receive chemotherapy along...

Read More

Overall survival gain with the addition of aflibercept to standard chemotherapy

Overall survival gain with the addition of aflibercept to standard chemotherapy

Posted by on Jan 16, 2014 in Colorectal cancer | 0 comments

In a nutshell This study estimated survival gain with the addition of aflibercept (Zaltrap) to standard chemotherapy among patients with metastatic colorectal cancer. Some background A combination chemotherapy regimen referred to as FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) is considered the standard of care in the treatment of...

Read More

Combination of capecitabine and bevacizumab

Combination of capecitabine and bevacizumab

Posted by on Jan 3, 2014 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the use of capecitabine in combination with bevacizumab (Avastin) in the treatment of unresectable metastatic colorectal cancer. Some background Current treatment of unresectable metastatic colorectal cancer (wide spread cancer that cannot be removed by surgery do to size or location) includes chemotherapy, such...

Read More

More risk with regorafenib

More risk with regorafenib

Posted by on Dec 6, 2013 in Colorectal cancer | 0 comments

In a nutshell This study examined whether there is an increased risk of hypertension among cancer patients being treated with regorafenib (Stivarga). Some background Vascular endothelial growth factor receptors (VEGF-r) are complexes on the surface of cells which stimulate the growth of new blood vessels, and are crucial for cancer growth and...

Read More